A composition for monitoring DNA damage includes a 3-ethynyl-5-nitroindolyl-2-deoxyribose compound or pharmaceutically acceptable salt thereof and a detectable moiety with a click-reactive functional group that is complementary to the alkyne group of the compound.

A composition for monitoring DNA damage includes a 3-ethynyl-5-nitroindolyl-2-deoxyribose compound or pharmaceutically acceptable salt thereof and a detectable moiety with a click-reactive functional group that is complementary to the alkyne group of the compound.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof,

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, W, n are defined as in the present application.

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof,

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, W, n are defined as in the present application.

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application, comprising ##STR00002##
reacting a compound represented by formula (II) with a compound represented by formula (III) in the presence of a condensation agent to obtain a compound represented by formula (I).

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application, comprising ##STR00002##
reacting a compound represented by formula (II) with a compound represented by formula (III) in the presence of a condensation agent to obtain a compound represented by formula (I).

A sulfinate glycosyl donor of formula I and a method for preparing same as well as use thereof in preparing a glycoside compound including a thioglycoside compound and a carbon glycoside compound are provided. The sulfinate glycosyl donor has a special sulfinate structure. When the sulfinate glycosyl donor is used as a raw material to prepare the glycoside compound, an additional initiator does not need to be added, such that the production cost is saved, the generation of byproducts is reduced, and the glycoside compound with a purity greater than 98% is obtained. The sulfinate glycosyl donor can be used in the preparation of the glycoside compound such as the thioglycoside compound and the carbon glycoside compound.

A sulfinate glycosyl donor of formula I and a method for preparing same as well as use thereof in preparing a glycoside compound including a thioglycoside compound and a carbon glycoside compound are provided. The sulfinate glycosyl donor has a special sulfinate structure. When the sulfinate glycosyl donor is used as a raw material to prepare the glycoside compound, an additional initiator does not need to be added, such that the production cost is saved, the generation of byproducts is reduced, and the glycoside compound with a purity greater than 98% is obtained. The sulfinate glycosyl donor can be used in the preparation of the glycoside compound such as the thioglycoside compound and the carbon glycoside compound.